NEW DELHI — India has slashed tuberculosis deaths by 38% since 2015, carving out critical gains against the world's deadliest bacterial infection even as international donors pull back their purses.
The progress arrived amid a precarious financial shift. According to the World Health Organisation's Global Tuberculosis Report 2026, domestic government budgets now finance 86% of all anti-TB programs worldwide. Foreign donor contributions shrank 14% in a single year, sinking from $1.1 billion in 2024 to $0.94 billion in 2025. For nearly a decade, international aid had hovered steadily between $1.1 billion and $1.3 billion annually. That safety net is fraying.
The disease killed 1.13 million people in 2025. It strikes down young and middle-aged adults during their prime earning years, concentrating more than 80% of its casualties across low- and middle-income nations. A full quarter of all global cases in 2025 remained clustered inside India.
The math behind TB eradication is falling behind. The United Nations high-level TB meeting set a target of raising $22 billion every year by 2027 to manage screening, diagnostic labs, patient care, and drug procurement. Current spending barely scratches that bar.
Across low- and middle-income territories, domestic spending generated $5.63 billion in 2025. Five emerging economic heavyweights — Brazil, China, India, the Russian Federation, and South Africa — provided $3.7 billion, or 65%, of that domestic pool. Laboratory science is starving just as badly. Research and development investments stood at $1.2 billion in 2023, missing the annual global innovation benchmark of $5 billion by more than 75%.
A disease rooted in social and economic vulnerability can only be eliminated as underlying systems become stronger," said Dhun Davar, deputy chief executive officer and chief of programmes at the Asian Venture Philanthropy Network.
Yet new clinical defenses are surfacing within Indian laboratories. Fresh trial data from indigenous vaccine candidates showed clear protection against extrapulmonary tuberculosis, validating domestic pushes for targeted immunisation across high-risk demographics alongside regular clinical interventions.
| Tuberculosis Metric (Global & Regional) | Verified Figure / Benchmark | Status / Trend |
|---|---|---|
| Global TB Deaths (2025) | 1.13 million | Leading single-agent infectious killer |
| India TB Mortality Reduction (2015–2025) | 38% decline | Major survival gain |
| India Share of Global Cases (2025) | 25% | Highest single-country burden |
| Global Domestic Funding Share | 86% | National governments carry load |
| International Donor Aid (2025) |
Geography dictates the battlefield. The WHO South-East Asia Region logged 3.6 million new tuberculosis cases in 2025 — 34% of the planet's total — and lost 400,000 lives to the bacterium.
Resources remain wildly misaligned with clinical reality. The region deployed $1.03 billion for prevention and clinical care in 2025, with national governments supplying 91% of that cash. But that sum represents just 16% of total global spending, forcing clinics to treat over a third of the world's patients on a shoestring budget.
"These numbers are a stark reminder that TB remains one of the Region’s most pressing public health and development challenges," said Dr. Nilesh Buddha, officer-in-charge at the WHO South-East Asia Regional Office.
Dr. Buddha pressed member states to turn high-level declarations into clinics, medicines, and active community outreach before statutory timelines run out.
Ending TB is not simply a health sector responsibility. It requires leadership across government, sustained investment, strong health systems and communities at the centre of the response. We have tools to prevent, diagnose and treat TB. What is needed now is the commitment to ensure they reach everyone who needs them, without delay or financial hardship.
Tuberculosis devastates personal finances long before it destroys lung tissue. Half of all tuberculosis patients and their families faced catastrophic financial shocks in 2025, spending more than 20% of their total annual household income on doctor fees, transport, laboratory work, and lost wages. The WHO End TB Strategy had established a firm global target of zero catastrophic costs.
Medical vulnerability also runs alongside common metabolic and nutritional deficits. The bacteria prey upon compromised immune systems, converting lifestyle and nutritional crises into active pulmonary illness.
Official figures revealed five distinct medical drivers behind 2025's new cases:
Undernutrition: Fuelled 0.96 million new infections, standing as the primary global trigger.
Type 2 Diabetes: Provoked 0.92 million cases as blood sugar dysregulation crippled natural defenses.
Alcohol Use Disorders: Sparked 0.73 million cases worldwide.
Tobacco Smoking: Drove 0.69 million active infections by inflaming respiratory tracts.
HIV Infection: Triggered 0.55 million cases through deep cellular immune loss.
For citizens, the medical guidance remains direct. Chronic cough persisting past two weeks, unexplained evening fevers, night sweats, and sudden weight loss demand immediate sputum and molecular testing at public diagnostic hubs. Stabilising daily blood sugar, correcting nutritional deficiencies with high-protein staples, and avoiding tobacco dramatically bolster cellular resistance against dormant bacterial flare-ups.
Health authorities across South-East Asia are now preparing for regional technical rounds to lock in emergency domestic allocations before the 2027 United Nations milestones arrive.
| $0.94 billion |
| Down 14% from $1.1B in 2024 |
| Annual Global Funding Target (by 2027) | $22.0 billion | Massive deficit in diagnostic access |
| South-East Asia Case Load (2025) | 3.6 million (34% global) | Regional epicenter |
| South-East Asia Annual Deaths | 400,000 (35% global) | High clinical urgency |
| Research & Development Spend (2023) | $1.2 billion | Target: $5.0 billion annually |